Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer by Royo, Felix et al.
Oncotarget6835www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 6
Transcriptomic profiling of urine extracellular vesicles reveals 
alterations of CDH3 in prostate cancer
Felix Royo1,2,*, Patricia Zuñiga-Garcia1,*, Verónica Torrano1,*, Ana Loizaga3,*, 
Pilar Sanchez-Mosquera1, Aitziber Ugalde-Olano4, Esperanza González1, Ana R. 
Cortazar1, Laura Palomo1, Sonia Fernández-Ruiz1, Isabel Lacasa-Viscasillas3, Maria 
Berdasco5, James D. Sutherland1, Rosa Barrio1, Amaia Zabala-Letona1, Natalia 
Martín-Martín1, Amaia Arruabarrena-Aristorena1, Lorea Valcarcel-Jimenez1, 
Alfredo Caro-Maldonado1, Jorge Gonzalez-Tampan3, Guido Cachi-Fuentes3, Manel 
Esteller5, Ana M. Aransay1,2, Miguel Unda3, Juan M. Falcón-Pérez1,2,6,Ω, Arkaitz 
Carracedo1,6,7,Ω
1CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain
2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Spain
3Department of Urology, Basurto University Hospital, Bilbao, Spain
4Department of Pathology, Basurto University Hospital, Bilbao, Spain
5Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
6Ikerbasque, Basque Foundation for Science, Bizkaia, Spain
7Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), Bizkaia, Spain
*These authors contributed equally to this work
ΩThese authors contributed equally to this work
Correspondence to:  Arkaitz Carracedo, e-mail: acarracedo@cicbiogune.es
 Juan M. Falcón-Pérez, e-mail: jfalcon@cicbiogune.es
Keywords: extracellular vesicles, exosomes, prostate cancer, urine biomakers
Received: August 18, 2015 Accepted: November 26, 2015 Published: January 12, 2016
ABSTRACT
Extracellular vesicles (EV) are emerging structures with promising properties for 
intercellular communication. In addition, the characterization of EV in biofluids is an 
attractive source of non-invasive diagnostic, prognostic and predictive biomarkers. 
Here we show that urinary EV (uEV) from prostate cancer (PCa) patients exhibit 
genuine and differential physical and biological properties compared to benign 
prostate hyperplasia (BPH). Importantly, transcriptomics characterization of uEVs led 
us to define the decreased abundance of Cadherin 3, type 1 (CDH3) transcript in uEV 
from PCa patients. Tissue and cell line analysis strongly suggested that the status of 
CDH3 in uEVs is a distal reflection of changes in the expression of this cadherin in the 
prostate tumor. CDH3 was negatively regulated at the genomic, transcriptional, and 
epigenetic level in PCa. Our results reveal that uEVs could represent a non-invasive 
tool to inform about the molecular alterations in PCa.
INTRODUCTION
In the recent years, the search of biomarkers in urine 
has focused on the characterization of urinary extracellular 
vesicles (uEVs), trying to overcome the complexity and 
variation of this biofluid [1, 2]. Under the denomination 
of uEVs, there is a complex mixture of vesicles, including 
exosomes, microvesicles and apoptotic bodies [3, 4]. 
Although there are no clear markers to distinguish them, 
exosomes are defined as small membrane vesicles with a 
diameter of 40–150 nm formed by inward budding of the 
membrane of late endosomes resulting in the formation 
of multivesicular bodies (MVB) fulfilled of intraluminal 
vesicles. Then, some of these (MVB) fuse to the plasma 
membrane releasing in this manner the exosomes to the 
extracellular milleu [5]. Microvesicles or ectosomes refer 
to plasma membrane shedding vesicles of 0.1–1 μm [6]. 
Apoptotic bodies are assumed to be of bigger size [7]. 
uEVs are released by several tissues along the urinary 
tract and their cargo varies depending on their origin [8]. 
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Evidence of the presence of uEVs belonging to prostate 
has been already reported [9, 10] and the cargo includes 
proteins of prostate origin such as prostate-specific 
membrane antigen (PSMA) [11]. Proteomic analysis of 
uEVs in PCa patients has been recently carried out with 
promising results as a source of biomarkers [12] and the 
use of microRNAs as markers for this disease have been 
also extensively reported and reviewed [13]. Most of 
the studies to date focus on the comparative analysis of 
healthy and PCa patients. This raises the question of the 
existence of biomarkers that can discriminate PCa from 
BPH [14], a pathology that has been shown to interfere 
with well established biomarkers such as prostate-specific 
antigen (PSA) [15]. In the present work, we aimed at 
identifying PCa biomarkers within uEVs through the 
analysis of the uEV transcriptome. We selected transcripts 
with a presence-absence pattern in BPH and PCa, and we 
extensively validated the candidate transcript encoded 
by the Cadherin 3, type 1 gene (CDH3). Importantly, 
we corroborated this observation in a miniaturized assay 
that could facilitate the translation of the results into the 
clinic. Finally, the analysis of mRNA in prostate tumor 
tissue from patients revealed alterations in this gene, 
coherent with genomic transcriptional and epigenetic 
changes, all pointing at the inhibition of CDH3 in PCa. 
Overall, our results support that analysis of uEVs could 
represent a non-invasive method to evaluate and monitor 
PCa alterations. 
RESULTS
Characterization of uEVs from BPH and PCa 
patients
As a first approach, we analyzed the physical 
characteristics of uEVs from patients with BPH and PCa by 
comparing more than 23–30 independent preparations from 
each group (Supplementry Table S1). In order to validate 
the ultracentrifugation procedure [16] for isolation of uEVs, 
the presence of double membrane vesicles by cryo-electron 
microscopy (Figure 1A) and EV markers by western blot [28] 
was confirmed (Supplementary Figure S1). We next analyzed 
uEV size and number in urine of BPH and PCa patients. 
Nanoparticle-tracking analysis (NTA) was performed 
in samples before and after urine ultracentrifugation. 
NTA-estimated particle number was comparable before 
(8.9e10 ± 1.47e10 particles/ml in BPH, and 9.3e10 ± 1.29e10 
particles/ml in PCa; mean ± s.e.m.; n = 5; p > 0.05) and was 
reduced in PCa after ultracentrifugation (2.49e8 ± 2.46e7 
particles/ml in BPH, and 1.56e8 ± 1.69e7 particles/ml in PCa; 
mean ± s.e.m.; p = 0.04) (Figure 1B). However, no significant 
changes were observed in particle size before (217 ± 13.2 nm 
in BPH, and 215.8 ± 6.9 nm in PCa; mean ± s.e.m.; n = 5; 
p > 0.05) or after ultracentrifugation (176.6 ± 6.7 nm in BPH, 
and 182.4 ± 6.9 nm in PCa; mean ± s.e.m.; n = 5; p > 0.05) 
(Figure 1C). It is worth noting that NTA analysis in 
samples before ultracentrifugation could detect non-uEV 
particles and contaminants as positive events (and hence 
explain the larger number and average size) while after 
filtration and ultracentrifugation the values obtained are 
more representative of an uEV-enriched preparation. 
Although no statistically significant differences were 
found, NTA analysis revealed a trend to a different 
size distribution of the uEVs, with a lower abundance 
of small vesicles (0–100 nm) and a greater abundance 
of large (150–200 nm) and very large (250–350 nm) 
vesicles in PCa when compared with BPH (Figure 1D). 
Of note, we observed a size discrepancy between TEM 
and NTA analysis of uEVs. Although it warrants further 
investigation, this fact is probably due to two main 
factors: the technology employed by NTA to determine 
particle size and the potential effect of the TEM sample 
preparation protocol on this parameter.
Further to this characterization, we analyzed the 
changes in cargo in BPH and PCa. RNA concentration per 
vesicle was comparable in BPH and PCa uEVs (0.017 ± 
0.006 ng RNA per million uEVs in BPH and 0.0046 ± 
0.0005 ng RNA per million uEVs in PCa; mean ± s.e.m.; 
n = 9–10; Mann Whitney U p = 0.13). Similarly, we did 
not observe significant differences in protein concentration 
(0.041 ± 0.01 µg protein per million uEVs in BPH and 
0.019 ± 0.003 µg protein per million uEVs in PCa; mean ± 
s.e.m.; n = 9–10; Mann Whitney U p = 0.18). 
Transcriptomic analysis of PCa and BPH uEVs
We next aimed at identifying molecular alterations 
in uEV cargo from PCa patients. It has been recently 
reported that these particles present a genuinely differential 
proteome in patients harboring PCa [12]. However, little 
is known about the transcript content of uEVs and the 
potential of these molecules to inform about the biological 
characteristics of PCa, especially when comparing to 
patients with BPH. To address this question, we extracted 
RNA of uEVs from BPH and PCa patient samples. First, 
we observed lack of overt changes in overall RNA size 
distribution (Figure 2A). Next, we labeled and hybridized 
BPH and PCa uEV-derived RNA into whole genome 
Illumina gene expression microarrays. The results showed 
the detection (detection p-value < 0.01) of 1336 unique 
transcripts in the two groups analyzed (presence in 50% 
of the cases in either group was defined as positive, 
Supplementry Table S3), 1010 in BPH and 956 in PCa 
(Figure 2B). Venn analysis revealed an overlap of 47.1% 
from total unique transcripts in BPH and PCa (Figure 2B). 
We performed a further step in candidate transcript 
selection by identifying genes that were selectively 
detected in one of the two biological settings (BPH or 
PCa, in at least 75% of the cases). Illumina platform 
provides information about the probability of a probe to 
present a signal that is different to background noise, for 
which purpose we established a confidence interval of 
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99% (p < 0.01). The list of differentially detected probes is 
shown in Figure 2C. In addition, we took advantage of the 
microarray analysis in order to define housekeeping genes 
that would have similar abundance in uEVs from BPH 
and PCa patients. To this end, starting from normalized 
signal values, we defined genes with no differential 
abundance (p-value > 0.95 and fold change no greater 
than ± 5%; Supplementry Table S4). From this analysis, 
we selected two transcripts, Eukaryotic Elongation Factor 
1A1 (EEF1A1) and Ribosomal Protein L6 (RPL6), that 
we monitored in subsequent studies. In addition, we also 
included Glyceraldehyde Phosphate Dehydrogenase 
(GAPDH) as a housekeeping gene supported by prior 
studies of our group [16].
Validation of uEV biomarkers of PCa
To ascertain the potential of candidate uEV transcripts, 
we performed qRTPCR from an independent set of 
ultracentrifuge-purified uEV retrotranscribed RNA (using an 
average of 1.5e7 uEVs per reaction). Firstly, the abundance 
of housekeeping transcripts (RPL6, EEF1A1, GAPDH) was 
strongly correlated (Supplementry Figure S2A), reinforcing 
the notion of their value as housekeeping transcripts. The 
use of these controls allowed us to identify 4 cases with 
lack of amplification in all three transcripts, which was 
considered an exclusion criterion for the analysis. Secondly, 
the evaluation of 10 transcripts of interest (From Figure 2C) 
revealed that two candidates, Cadherin 3, type 1 (CDH3) 
and CKLF-Like MARVEL Transmembrane Domain 
Figure 1: Physical characterization of uEVs from PCa and BPH samples. (A) Representatives cryo-TEM micrographs of uEVs 
isolated from BPH and PCa urine samples. Bar, 100 nm. n = 3. (B and C) Box-plots showing number (B) or size (C) of particles isolated 
from each group, indicating the mean and s.e.m. (n = 23 fo BPH and 30 for PCa). (D) Size distribution of the particles isolated from each 
preparation (Mean ± s.e.m. is depicted, n = 23 fo BPH and 30 for PCa). Statistic test: Student t test.
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Containing 3 (CMTM3), exhibited the predicted behavior 
in the validation dataset (Figure 2D). These two transcripts 
were predominantly detected in BPH uEVs, whereas the 
detection rate was below 30% in PCa uEVs. Of note, 
we confirmed that these transcripts were contained in 
uEVs, since they exhibited resistance to RNase treatment 
(Supplementary Figure S2B).
Our results demonstrate that we can identify 
transcripts with differential abundance in PCa uEVs, 
employing 50 mL of urine and using an ultracentrifugation-
based method for uEV isolation [16]. However, biomarker 
identification requires miniaturization of the assay with 
the consequent scaling down of the starting material. To 
refine our detection method, we employed a commercial 
exosomal RNA purification procedure (Norgen Biotek) in 
an independent set of samples that allowed us to reduce 
urine volume to 10 mL. We then performed qRTPCR from 
Norgen-purified retrotranscribed RNA. We evaluated the 
expression level of the two best candidates, CMTM3 and 
CDH3. As shown before, the two housekeeping transcripts 
employed (GAPDH and RPL6) exhibited a strong and 
significant correlation (Supplementry Figure S2C). 
Interestingly, this purification method precluded detection 
of CMTM3, while recapitulated the reduction in CDH3 
with higher sensitivity using normalization against RPL6 
(0.69 ± 0.1; mean ± s.e.m.; p = 0.055) and GAPDH (0.65 
± 0.08; mean ± s.e.m.; p = 0.01) (Figure 2E). 
Taken together, our transcriptomic analysis reveals 
that CDH3 abundance is reduced in PCa uEVs and sets the 
basis for PCa biomarker search based on uEV transcript 
analysis. 
uEVs are indicators of PCa alterations
Our results convincingly show that CDH3 
abundance is reduced in uEVs from PCa patients. On the 
basis of these results, we hypothesized that the alteration 
observed in uEVs might be a reflection of transcriptomic 
changes in the prostate tumor.
In order to confirm our hypothesis, we studied the 
expression of CDH3, in a set of BPH and PCa tissue 
specimens. The results of CDH3 expression analysis 
demonstrated that it was significantly decreased in tissue 
from patients with PCa compared to BPH (0.52 ± 0.12; 
mean ± s.e.m.; p = 0.018), in full coherence with our 
observation in uEVs (Figure 3A). Of note, these results 
could lead to the notion that the association between 
transcriptomic tumor cell landscape and exosome RNA 
cargo correlate at high frequency. However, prior studies 
from our lab showed that known cancer genes, such as 
PTEN, do not exhibit a direct correlation between uEVs 
mRNA abundance and PTEN tumor alterations [16], 
suggesting a selective process in cargo loading into uEVs. 
Next, we ascertained the potential extrapolation 
of this observation to other biological contexts, such 
as a panel of benign prostate cells and metastatic 
prostate cancer cell lines and large human PCa datasets. 
Interestingly, the expression of CDH3 in prostate cell lines 
revealed a down-regulation of the transcript in metastatic 
cancer cell lines (black), compared to benign-immortalized 
cells (grey) (0.17 ± 0.07; mean ± s.e.m.) (Figure 3B). 
Importantly, this observation was confirmed in two datasets 
where the expression of PCa specimens was compared to 
biopsies from healthy patients [24, 25] (Figure 3C) and 
was in full agreement with a previous report [29].
We also monitored the expression levels of other 
transcripts identified in uEVs. On the one hand, CMTM3 
expression, which was shown to be down-regulated in the 
ultracentrifugation uEVs (but not detected with Norgen 
extraction method), showed a significant reduction in 
PCa compared with BPH tissues, but this result was 
not reproduced in publicly available PCa datasets 
and exhibited only a modest trend in PCa cell lines 
(Supplementary Figure S3A–S3C). On the other hand, 
our housekeeping genes RPL6 and EEF1A1 showed no 
consistent alterations throughout the same analytical 
layout (Supplementary Figure S3A–S3C). 
We next ask whether the reduction of CDH3 
expression observed in PCa could be extrapolated to other 
urogenital cancers. Data mining analysis was performed 
in bladder and renal cancer datasets (www.oncomine.
org, [30]). Although there was certain consistency in the 
alteration of CDH3 expression within the same tumor type, 
the directionality of the alterations was not preserved among 
the different tumor types (Supplementary Figure S3D). 
In order to address whether gene expression 
alterations in CDH3 could be translated in a decrease in the 
protein expression, we took advantage on publicly available 
initiatives for immunoreactivity analysis. Proteinatlas 
(www.proteinatlas.org, [31–35]) allows the visualization 
of immunohistochemistry (IHC) staining in a wide array 
of tissues. There was data available for CDH3 staining 
with high quality IHC-specific antibodies. Importantly, 
the staining in normal prostate epithelia corroborated the 
staining of basal prostate epithelial cells, in agreement 
with reports in this and other epithelial tissues [29, 36, 37] 
(Figure 3E, middle panel and Supplementary Figure S3F). 
As predicted, CDH3 expression was decreased in PCa 
specimens. This result was particularly evident in tumor 
samples with adjacent non-neoplastic tissue (Figure 3D). 
Interestingly, CDH3 sub-cellular distribution was altered 
in tumor cells, with a predominant loss of membrane 
immunoreactivity (Figure 3D).
We next asked the molecular cues leading to the 
down-regulation of CDH3 in PCa. On the one hand, we 
studied the genomic and epigenetic changes occurring 
in CDH3 locus. The genomic analysis showed frequent 
shallow deletions of CDH3 in four independent PCa 
datasets (Figure 4A, [24, 25, 38, 39]). Moreover, 
epigenetic analysis of CDH3 promoter indicated increased 
methylation in PCa and a correlation between the 
methylation status of the locus and the transcript abundance 
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(Figure 4B, 4C; [38, 39]), in line with a previous report 
[29]). On the other hand, we evaluated the association 
of CDH3 expression with well-known upstream 
regulators. Tp63 is a basal prostate epithelial marker 
which is down-regulated in PCa specimens [40–42], 
and that has been reported to regulate CDH3 expression 
[43]. We found a strong correlation between the mRNA 
expression of Tp63 and CDH3 in prostate specimens, 
which suggests that transcriptional regulation of this 
cadherin downstream p63 is at play in PCa (Figure 4D). 
Altogether, our results indicate that genomic loss, 
transcriptional regulation and promoter methylation 
contribute to the down-regulation of CDH3 in PCa. 
DISCUSSION
Extracellular vesicles including exosomes have 
been detected and characterized in urine [2, 44, 45]. 
These vesicles vary in composition and are associated 
with different diseases [12, 46]. Importantly, recent 
evidence suggests that PCa might exhibit alterations in 
the composition of uEVs [12, 47, 48]. The majority of 
Figure 2: Transcriptomic analysis of uEVs reveals transcripts with differential abundance in BPH and PCa. 
(A) Representative analysis of RNA size distribution obtained from the Bioanalyzer analysis of uEV preparations. n = 4–6. (B) Venn 
diagram depicting the number of unique transcripts identified in each experimental condition (n = 4 for BPH and n = 6 for PCa). 
(C) Transcripts exhibiting a presence-absence pattern in BPH and PCa. The transcripts shown complied with the requirements of being absent 
in one condition and with a minimum presence of 75% of cases in the other. Detection p-value is presented, where a limit was established in 
p < 0.01 in the microarray analysis (significant conditions are highlighted in pink or green in BPH and PCa, respectively). (D) Detection of 
ultracentrifugation-purified candidate uEV transcripts by qRTPCR. Detection was established as consistent amplification in the technical 
settings employed in the assay. n = 7 for BPH and n = 9 for PCa. (E) Transcript abundance of CDH3 relative to GADPH (left) and RPL6 
(right) in Norgen-purified uEVs-associated RNA samples. n = 6–7 for BPH and n = 18 for PCa. FU: fluorescence units. S: seconds. Error 
bar represents s.e.m. a.u. = Arbitrary units. Statistic test: Mann Whitney U test (E).
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Figure 3: CDH3 expression is reduced in PCa specimens. (A) CDH3 expression in tissue biopsies from BPH and PCa. CDH3 
expression relative to GAPDH is shown. n = 14 for BPH and n = 15 for PCa. (B) CDH3 expression in a panel of metastatic prostate cancer 
cell lines (black bars) and benign immortalized prostate cell lines (grey bars) relative to beta-Actin. n = 3. (C) CDH3 expression in two 
PCa datasets (Taylor PCa n = 150, normal n = 29; Grasso PCa n = 76, normal n = 12). (D) Representative images of immunohistochemical 
detection of CDH3 protein in PCa. Middle panel corresponds to a normal area and right panel to high grade PCa (HG PCa). Data source: 
Human Protein Atlas. Statistic test: Mann Whitney U test (A), Student t test (C).
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the studies are carried out comparing healthy individuals 
with PCa patients. It is worth noting that there is an 
increasing incidence of BPH in association with age [14], 
and the interference that this might introduce to biomarker 
identification is poorly understood. To address this 
question, we have performed a transcriptomics analysis 
comparing the mRNA content of uEVs from patients with 
BPH or PCa. The results reveal that urine from these two 
groups have significant alterations in vesicle number. 
Little is known about alterations in EV production in 
different pathologies as compared to the nature of its cargo 
and this aspect warrants further investigation. Importantly, 
we found a markedly different transcriptomics profile 
in uEVs from BPH and PCa. We were able to reduce a 
whole genome analysis (which revealed 1336 transcripts 
detected in uEV preparations) to two candidate transcripts 
(CMTM3 and CDH3) with decreased abundance in PCa. 
Interestingly, the miniaturization of the assay employing 
an alternative purification method revealed that CMTM3 
detection is sensitive to the approach used. This suggests 
that the detection of uEV transcripts might be affected 
by the uEV purification protocol and calls for further 
refinement and characterization of the selectivity and 
specificity of the uEV isolation methods. 
Placental cadherin (P-Cad or CDH3) has been widely 
studied in cancer [37, 49–59]. This protein regulates cell-cell 
adhesion processes and cellular differentiation. Interestingly, 
both oncogenic and tumor suppressive activities of this gene 
have been described in tissue-specific manner [37, 49–59]. 
We observe that CDH3 mRNA levels are down-regulated 
in PCa. This is coherent with preliminary observations 
at the protein level. It has been suggested that CDH3 is 
down-regulated and exerts tumor suppressive functions in 
hepatocellular carcinoma [50] and a prior study reported 
changes of CDH3 in PCa [29]. Our data suggest that CDH3 
may be exerting tumor suppressive activities in PCa.
Figure 4: Evaluation of the molecular events accounting for CDH3 down-regulation in PCa. (A) Analysis of the genomic 
alterations in CDH3 locus in four PCa databases (Taylor n = 93, Grasso n = 61, TCGA n = 258, Broad n = 56). (B and C) Promoter 
methylation analysis from TCGA database evaluating methylation in CDH3 locus (B) n = 49 for normal tissue, n = 101 acinar PCa and 
n = 196 for PCa) and the correlation between methylation status and CDH3 mRNA expression (C) n = 294). (D) Correlation analysis 
between CDH3 and Tp63 expression in two independent datasets. (Grasso, n = 49; Taylor, n = 131; primary tumors). Statistic test: Student 
t Test (B); Pearson´s coefficient (R) (C, D).
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We show that the regulation of CDH3 expression in 
PCa occurs at multiple levels. On the one hand, genomic 
and epigenetic analysis strongly suggests that deletion 
and methylation of the locus accounts for changes 
in expression. On the other hand, we find potential 
regulations at the level of upstream transcriptional 
regulators. Prior studies showed that CDH3 is a basal 
epithelial cell marker [29, 37]. Interestingly, Tp63, 
an upstream regulator of CDH3 [36], presents similar 
behavior to our gene of interest. Tp63 localizes to basal 
epithelial cells and is down-regulated in PCa [40–42, 60]. 
Our correlation analysis in public PCa supports the notion 
that p63 is a transcriptional upstream regulator of CDH3.
Of note, immunoreactivity analysis has provided 
preliminary evidence of mis-localization of CDH3 in PCa 
cells compared to non-tumoral counterparts, Interestingly, 
this alteration is also observed in other cancers and is 
associated to poor prognosis [59].
Altogether, our data show multiple means 
of regulation (genomic loss, DNA methylation, 
transcriptional regulation, and protein mis-localization) 
that could potentially lead to the alteration of CDH3 
function in PCa.
The function of EVs in cell communication and 
cancer aggressiveness has emerged in the past years [61, 62]. 
While their use as source of biomarkers is under intense 
investigation, there is limited evidence about their 
potential role as readouts of the tumoral genetic alterations 
[9]. This study informs about the properties of uEVs to 
reflect genetic alterations in the tumor of origin. We 
find that the decrease in abundance of CDH3 in uEVs 
is coherent with mRNA changes in the prostate tumor 
cells. This data opens new avenues in the non-invasive 
characterization of genetic alterations in PCa using uEVs, 
with the consequent potential for patient stratification.
MATERIALS AND METHODS
Patient samples and cell lines analysis
All urine samples were obtained from the Basque 
Biobank for research (BIOEF, http://www.biobancovasco.
org, Basurto University Hospital) upon informed consent 
and with evaluation and approval from the corresponding 
ethics committee (CEIC code OHEUN11-12 and 
OHEUN14-14). Inclusion criteria: For BPH patients, 
samples were obtained from cases with normal PSA, 
with symptomatic alterations (polyuria, distress), and 
that were scheduled for surgery. For PCa cases, samples 
were obtained from patients with primary localized 
cancer diagnosed de novo and that were scheduled for 
radical prostatectomy. Urine (40–100 ml) was collected 
by spontaneous urination between 8–10 AM, in fasting 
conditions. Patient information, tumor characteristics 
and urine volume is described in Supplementry Table S1. 
For prostate tissue specimens, samples were prepared and 
diagnosed as described in [16]. Cell lines were cultured as 
described in [17] and RNA was harvested in conditions of 
exponential growth.
Urine extracellular vesicle purification
uEV isolation by ultracentrifugation was performed 
as described in [16]. Briefly, urine was centrifuged at 
2000 × g for 5 min to remove cell debris and filtered 
through 0.22 μm pore-filter before frozen at −80°C. For 
uEV isolation sample was thawed and subjected to two 
sequential centrifugations of 11500 × g for 30 min and 
second 118000 × g for 90 minutes. The pellet containing 
uEVs was resuspended in 150 μl of cold PBS and frozen 
for later processing. RNase treatment was not performed 
unless otherwise specified.
Western blot
Western blot was performed as described [18], using 
CD26 (Abcam, Cambridge, UK), CD63 (clone H5C6; from 
Developmental Studies Hybridoma Bank, Iowa, US), CD13 
(clone 3D8; from Santa Cruz Biotechnology Inc.), FLT1 
(clone 18; from BD Biosciences) and AQP2 (Sigma-Aldrich) 
antibodies.
Transmission electron microscopy (TEM) 
analysis
For cryo-electron microscopy, uEV preparations 
were directly adsorbed onto glow-discharged holey 
carbon grids (100 Holey carbon film of Cu with mess 
200; Quantifoil®, Germany). Grids were blotted at 95% 
humidity and rapidly plunged into liquid ethane with 
the aid of VITROBOT (Maastricht Instruments BV, 
The Netherlands). Vitrified samples were imaged at 
liquid nitrogen temperature using a JEM-2200FS/CR 
transmission cryo-electron microscope (JEOL, Japan) 
equipped with a field emission gun and operated at an 
acceleration voltage of 200 kV.
Size analysis and size distribution
Size distribution within uEV preparations was 
analyzed by nanoparticle-tracking analysis (NTA) by 
measuring the rate of Brownian motion using a NanoSight 
LM10 system (Malvern, U.K.), which is equipped with 
a fast video capture and particle-tracking software. 
NTA post-acquisition settings were kept constant for all 
samples, and each video was analyzed to give the mean, 
mode, and median vesicle size, as well as an estimation of 
the concentration [19]. For each preparation, two videos of 
30 seconds each were taken. For each video, at least 200 
tracks were completed in post-capture tracking analysis.
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Transcriptomic analysis
Total RNA isolation from uEV was achieved 
by RNeasy columns (Qiagen, Inc). The integrity, size 
and quantification were evaluated in RNA Pico Chips 
(Bioanalyzer; Agilent Technologies). For transcriptomic 
analysis of mRNA-associated uEVs, Illumina whole 
genome (HumanHT-12_V4.0; DirHyb, nt) method was 
used as reported [20]. cRNA synthesis was obtained out of 
2–25 ng of Total RNA, with TargetAmp™ Nano-g™ Biotin-
aRNA Labeling Kit for the Illumina® System (Epicentre, 
Cat# TAN07924) and subsequent amplification, labelling 
and hybridization were performed according to “Whole-
Genome Gene Expression Direct Hybridization” 
Illumina Inc.’s protocol, except the hybridization 
cRNA concentration, which was 285 ng instead of the 
standard 750 ng. Raw expression data were background-
corrected, log2-transformed and quantile-normalized 
using the lumi R package [21], available through the 
Bioconductor repository. Probes with a “detection 
p-value” lower than 0.01 in at least one sample were 
regarded as detected.
Retrotranscription and quantitative real time 
PCR analysis
To extract RNA from uEVs isolated by 
ultracentrifugation, we employed miRCURY™ RNA 
Isolation Kit Cell & Plant (Exiqon). In average, 1.5e7 
vesicles were used per retrotranscription reaction. In 
addition, a set of samples was extracted by Norgen 
Biotek Exosomal RNA purification kit, following 
the manufacturers’ instructions. For cell lines, RNA 
was extracted using NucleoSpin® RNA isolation kit 
from Macherey-Nagel (ref: 740955.240C). cDNA 
was synthesized from 0.1–1 µg of RNA using 
Superscript III (Life Technologies) following the 
manufacturer’s recommendations. For prostate tissue 
samples, RNA was extracted as reported in [16]. 
Quantitative Real Time PCR (Taqman qRTPCR) was 
performed as previously described [18]. Universal 
Probe Library (Roche) primers and probes employed 
are detailed in Supplementary Table S2. β-ACTIN 
(Hs99999903_m1) and GAPDH (Hs02758991_g1) 
housekeeping assays were from Applied Biosystems and 
showed similar results.
DNA methylation
Raw intensity CDH3 DNA methylation was 
extracted from The Cancer Genome Atlas dataset (https://
tcga-data.nci.nih.gov/tcga/) based on Illumina’s 450K 
methylation array. Data analysis from normal tissues 
(n = 49), prostate carcinoma (n = 196) and acinar prostate 
carcinoma (n = 101) were included. A three step-based 
normalization procedure was performed using the lumi 
[21] package available for Bioconductor [22], under 
the R statistical environment [23], consisting in color 
bias adjustment, background level adjustment and 
quantile normalization across arrays, as specified in [21]. 
Methylation level (β-value) for each of the 485, 577 CpG 
sites was calculated as the ratio of methylated signal 
divided by the sum of methylated and unmethylated signals 
plus 100. After normalization step, probes related to X and 
Y chromosomes were removed as well as those containing 
a SNPs with a frequency > 1% (1000 Genome project) 
in the probe sequence or interrogated CpG site.
Bioinformatics analysis and statistics
The following statistical analysis were employed:
Database normalization: all the datasets used for 
the data mining analysis were downloaded from GEO and 
subjected to background correction, log
2
 transformation 
and quartile normalization. In the case of using a 
pre-processed dataset, this normalization was reviewed 
and corrected if required.
For CDH3 genomic analysis, data from PCa patients 
with copy number alteration information in Taylor [24], 
Grasso [25], Broad/Cornell [26] and Robinson [27] et al. 
datasets was extracted from cbioportal.org. 
Correlation analysis
Pearson correlation test was applied to analyze 
the relation between paired genes. From this analysis, 
Pearson’s coefficient (R) indicates the existing linear 
correlation (dependence) between two variables X and Y, 
giving a value between +1 and −1 (both included), where 
1 is total positive correlation, 0 is no correlation, and −1 
is total negative correlation. The p-value indicates the 
significance of this R coefficient.
Statistical analysis
Data represent mean ± s.e.m. of pooled experiments 
unless otherwise stated. For data mining analysis, ANOVA 
test was used for multi-component comparisons. Student T 
test or Mann Whitney U test for two-group parametric or 
non-parametric comparisons, respectively. The confidence 
level used for all the statistical analyses was of 0.95 (alpha 
value = 0.05). Two-tail statistical analysis was applied for 
experimental design without predicted result and one-tail 
for validation experiments.
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